UsTekinumab for the Treatment Of Patients With Active Ankylosing Spondylitis (TOPAS) - a 28-week, Prospective, Open-label, Proof-of-concept Study.

Trial Profile

UsTekinumab for the Treatment Of Patients With Active Ankylosing Spondylitis (TOPAS) - a 28-week, Prospective, Open-label, Proof-of-concept Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TOPAS
  • Most Recent Events

    • 28 Jan 2014 New source identified and integrated (European Clinical Trials Database:EudraCT2011-000844-56).
    • 12 Jan 2014 Primary endpoint 'Assessments-in-Ankylosing-Spondylitis-40%-response-criteria' has been met.
    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top